Studies on sensitivity of zebrafish as a model organism for Parkinson′s disease: Comparison with rat model

Journal of Pharmacology and Pharmacotherapeutics

Volumn 5, Issue 1, 2014, Pages 39-46

  Makhija, Dinesh T ^a   Jagtap, Aarti G ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

3 4; 5 dimethylthia zol 2 yl 2; 5 diphenyltetrazolium bromide; Catalepsy; zebrafish

Indexed keywords

BROMOCRIPTINE; HALOPERIDOL; PRAMIPEXOLE; QUERCETIN; RESVERATROL; ROTENONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BAR TEST; BLOCK TEST; BRAIN SYNAPTOSOME; CATALEPSY; CONTROLLED STUDY; DISEASE MODEL; EXPERIMENTAL TEST; FEMALE; LOCOMOTION; MALE; NONHUMAN; PARKINSON DISEASE; RAT; SENSITIVITY ANALYSIS; SPECIES DIFFERENCE; SWIMMING; ZEBRA FISH;

EID: 84892734212     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.124422     Document Type: Article

References (25)

1. Barros TP, Alderton WK, Reynolds HM, Roach AG, Berghmans S. Zebrafish: An emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br J Pharmacol 2008;154:1400-13.
2. Tierney KB. Behavioural assessments of neurotoxic effects and neurodegeneration in zebrafish. Biochim Biophys Acta 2011;1812:381-9.
3. Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson's disease. J Biomed Biotechnol 2012;1152:1-9.
4. Flinn L, Bretaud S, Lo C, Ingham PW, Bandmann O. Zebrafish as a new animal model for movement disorders. J Neurochem 2008;106:1991-7.
5. Giacomini NJ, Rose B, Kobayashi K, Guo S. Antipsychotics produce locomotor impairment in larval zebrafish. Neurotoxicol Teratol 2006;28:245-50.
6. Flinn L, Mortiboys H, Volkmann K, Köster RW, Ingham PW, Brandmann O. Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio). Brain 2009;132:1613-23.
7. Sheng D, Qu D, Kwok KH, Ng SS, Lim AY, Aw SS, et al. Deletion of the WD40 domain of LRRK2 in zebrafish causes Parkinsonism-like loss of neurons and locomotive defect. PLOS Genet 2010;6:1-11.
8. Anichtchik O, Diekmann H, Fleming A, Roach A, Goldsmith P, Rubinsztein DC. Loss of PINK1 function affects development and results in neurodegeneration in zebrafish. J Neurosci 2008;28:8199-207.
9. Seibt KJ, Oliveira RL, Zimmermann FF, Capiotti KM, Bogo MR, Ghisleni G, et al. Antipsychotic drugs prevent the motor hyperactivity induced by psychotomimetic MK-801 in zebrafish (Danio rerio). Behav Brain Res 2010;214:417-22.
10. Perez-De La Cruz V, Gonzalez-Cortes C, Pedraza-Chaverri J, Maldonado PD, Andres-Martinez L, Santamaría A. Protective effect of S-allylcysteine on 3-nitropropionic acid-induced lipid peroxidation and mitochondrial dysfunction in rat brain synaptosomes. Brain Res Bull 2006;68:379-83.
11. Santamaría A, Salvatierra-Sanchez R, Vazquez-Roman B, Santiago-Lopez D, Villeda-Hernandez J, Galvan-Arzate S, et al. Protective effects of the antioxidant selenium on quinolinic acid-induced neurotoxicity in rats: In vitro and in vivo studies. J Neurochem 2003;86:479-88.
12. Bishnoi M, Chopra K, Kulkarni SK. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol 2006;552:55-66.
13. Mandhane SN, Chopde CT, Ghosh AK. Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats. Eur J Pharmacol 1997;328:135-41.
14. Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: New insights into their cellular reduction. Biotechnol Annu. Rev 2005;11:127-52.
15. Bové J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005;2:484-94.
16. Singh N, Pillay V, Choonara YE. Advances in the treatment of parkinson's disease. Prog. In Neurobiol 2007;81:29-44.
17. Schapira AH. Neuroprotection in PD: A role for dopamine agonists? Neurology 2003;61 (6 Suppl 3):S34-42.
18. Schapira AH, Olanow CW. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann Neurol 2003;53 Suppl 3:S149-59.
19. Goldsmith P. Zebrafish as a pharmacological tool: The how, why and when. Curr Opin Pharmacol 2004;4:504-12.
20. Bretaud S, Lee S, Guo S. Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease. Neurotoxicol Teratol 2004;26:857-64.
21. Gerlai R, Lahav M, Guo S, Rosenthal A. Drinks like a fish: Zebra fish (Danio rerio) as a behavior genetic model to study alcohol effects. Pharmacol Biochem Behav 2000;67:773-82.
22. Swain HA, Sigstad C, Scalzo FM. Effects of dizoclipine (MK-801) on circling behavior, swimming activity and place preference in zebrafish (Danio rerio). Neurotoxicol Teratol 2004;26:725-9.
23. Echevarria DJ, Hammack CM, Pratt DW, Hosemann JD. A novel behavioural test battery to assess global drug effects using the zebrafish. Int J Comp Psychol 2008;21:19-34.
24. Iturriaga-Vasquez P, Osorio F, Riquelme S, Catro S, Herzog R. Zebrafish: A model for behavioural pharmacology. Rev Farmacol Chile 2012;5:27-32.
25. Ghosh A, Dhumal VR, Tilak AV, Singh A, Pandey M, Bondekar AA. Effect of chronic administration of low dose of aspirin on haloperidol induced catalepsy in rats. J. Pharmacol Pharmacother 2011;2:198-9.